Complement Activation, Immunogenicity, and Immune Suppression as Potential Side Eff ects of Liposomes - Harnessing Biomaterials in Nanomedicine: Preparation, Toxicity, and Applications - page 327

12. Belchetz, P. E., Crawley, J. C., Braidman, I. P., and Gregoriadis, G.
(1977). Treatment of Gaucher's disease with liposome-entrapped
glucocerebroside: beta-glucosidase. Lancet 8029, pp. 116-117.
13. Bergers, J. J., Otter, W. D., and Crommelin, J. A. (1996). Liposome-based
cancer vaccines. J. Liposome Res . 6, pp. 339-355.
14. Bonte, F., and Juliano, R. L. (1986). Interactions of liposomes with
serum proteins. Chem. Phys. Lipids 40, pp. 359-372.
15. Cabriales, S., Bresnahan, J., Testa, D., Espina, B. M., Scadden, D. T., Ross,
M., and Gill, P. S. (1998). Extravasation of liposomal daunorubicin in
patients with AIDS-associated Kaposi's sarcoma: a report of four cases
Oncol. Nurs. Forum 25, pp. 67-70.
16. Chanan-Khan, A., Szebeni, J., Savay, S., Liebes, L., Rafique, N. M., Alving,
C. R., and Muggia, F. M. (2003). Complement activation following first
exposure to pegylated liposomal doxorubicin (Doxil): possible role in
hypersensitivity reactions. Ann. Oncol. 14, pp. 1430-1437.
17. Chonn, A., Cullis, P. R., and Devine, D. V. (1991). The role of surface
charge in the activation of the classical and alternative pathways of
complement by liposomes. J. Immunol . 146, pp. 4234-4241.
18. Chopra, R., Blair, S., Strang, J., Cervi, P., Patterson, K. G., and Goldstone,
A. H. (1991). Liposomal amphotericin B (AmBisome) in the treatment
of fungal infections in neutropenic patients. J. Antimicrob. Chemother.
28 Suppl B, pp. 93-104.
19. Ciftcioglu, N., McKay, D. S., Mathew, G., and Kajander, E. O. (2006).
Nanobacteria: fact or fiction? Characteristics, detection, and medical
importance of novel self-replicating, calcifying nanoparticles. J.
Investig. Med . 54, pp. 385-394.
20. Cunningham, C. M., Kingzette, M., Richards, R. L., Alving, C. R., Lint, T. F.,
and Gewurz, H. (1979). Activation of human complement by liposomes:
a model for membrane activation of the alternative pathway. J. Immunol.
122, pp. 1237-1242.
21. Danenberg, H. D., Golomb, G., Groothuis, A., Gao, J., Epstein, H.,
Swaminathan, R. V. P., Seifert, P., and Edelman, E. R. (2003). Liposomal
alendronate inhibits systemic innate immunity and reduces in-stent
neointimal hyperplasia in rabbits. Circulation 108, pp. 2798-2804.
22. de Marie, S. (1996). Liposomal and lipid-based formulations of
amphotericin B. Leukemia 10, Suppl. 2., pp. S93-S96.
23. Deamer, D. (2009). On the origin of systems. Systems biology, synthetic
biology and the origin of life. EMBO Rep . 10, Suppl 1, pp. S1-4.
24. Deamer, D. W. (2008). Origins of life: how leaky were primitive cells?
Nature 454 (7200), pp. 37-38.